Douglas G. McNeel, MD, PhD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.
Specialties
UW Health Clinics
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)
Languages Spoken
| English, French |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Internal Medicine
Medical Oncology |
| Fellowship |
University of Washington School of Medicine, Seattle
Fred Hutchinson Cancer Research Center |
| Residency |
University of Washington School of Medicine, Seattle
|
| Internship |
University of Washington School of Medicine, Seattle
|
| Medical School |
University of Chicago, Pritzker School of Medicine, Chicago, IL, 1994
|
Awards/Honors
Programs & Conditions
PubMed Articles
-
Olson BM McNeel DG .
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013;3:109
[PubMed ID: 23653893]
-
Cetnar J Wilding G McNeel D Loconte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
-
Olson BM Johnson LE McNeel DG .
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013 Mar;62(3):585-96
[PubMed ID: 23108626]
-
Olson BM Jankowska-Gan E Becker JT Vignali DA Burlingham WJ McNeel DG .
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601
[PubMed ID: 23152566]
-
Bloom JE McNeel DG Olson BM .
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines. 2012 Dec;11(12):1401-4
[PubMed ID: 23252384]
-
Johnson LE Frye TP McNeel DG .
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 2012 Dec 1;1(9):1546-1556
[PubMed ID: 23264901]
-
Bruce JY Lang JM McNeel DG Liu G .
Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22
[PubMed ID: 23271258]
-
Olson BM McNeel DG .
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines. 2012 Nov;11(11):1315-7
[PubMed ID: 23249231]
-
Morse MD McNeel DG .
T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate. 2012 Aug 1;72(11):1239-47
[PubMed ID: 22213030]
-
McNeel DG Smith HA Eickhoff JC Lang JM Staab MJ Wilding G Liu G .
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47
[PubMed ID: 22210552]
-
Johnson LE McNeel DG .
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate. 2012 May 15;72(7):730-40
[PubMed ID: 22529020]
-
Smith HA Cronk RJ Lang JM McNeel DG .
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 2011 Nov 1;71(21):6785-95
[PubMed ID: 21880588]
-
Lang JM Kaikobad MR Wallace M Staab MJ Horvath DL Wilding G Liu G Eickhoff JC McNeel DG Malkovsky M .
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011 Oct;60(10):1447-60
[PubMed ID: 21647691]
-
Smith HA McNeel DG .
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother. 2011 Oct;34(8):569-80
[PubMed ID: 21904219]
-
Olson BM McNeel DG .
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother. 2011 Jun;60(6):781-92
[PubMed ID: 21350948]
-
Maricque BB Eickhoff JC McNeel DG .
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate. 2011 Feb 1;71(2):134-46
[PubMed ID: 20632317]
-
Smith HA Maricque BB Eberhardt J Petersen B Gulley JL Schlom J McNeel DG .
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol. 2011;2011:454861
[PubMed ID: 21197272]
-
Gao JJ Maricque BB Morse MD Huang W McNeel DG .
Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol. 2010 Nov 20;28(33):e680-3
[PubMed ID: 20805455]
-
Alam S McNeel DG .
DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines. 2010 Jul;9(7):731-45
[PubMed ID: 20624047]
-
Becker JT Olson BM Johnson LE Davies JG Dunphy EJ McNeel DG .
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010 Jul-Aug;33(6):639-47
[PubMed ID: 20551832]
-
Olson BM Frye TP Johnson LE Fong L Knutson KL Disis ML McNeel DG .
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun;59(6):943-53
[PubMed ID: 20140431]
